Press coverage about MYOS RENS Technology (NASDAQ:MYOS) has trended somewhat positive on Friday, according to Accern Sentiment Analysis. The research firm scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. MYOS RENS Technology earned a media sentiment score of 0.08 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.6977346405469 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the near term.
Shares of MYOS RENS Technology (NASDAQ:MYOS) traded down $0.01 during trading hours on Friday, hitting $1.47. The stock had a trading volume of 66,100 shares, compared to its average volume of 242,000. MYOS RENS Technology has a twelve month low of $1.08 and a twelve month high of $6.98. The stock has a market capitalization of $9.39, a P/E ratio of -2.23 and a beta of 1.47.
MYOS RENS Technology (NASDAQ:MYOS) last issued its quarterly earnings data on Tuesday, November 14th. The company reported ($0.13) earnings per share (EPS) for the quarter. MYOS RENS Technology had a negative net margin of 941.41% and a negative return on equity of 71.14%. The company had revenue of $0.16 million during the quarter.
About MYOS RENS Technology
MYOS RENS Technology Inc (MYOS), formerly MYOS Corporation, is an early-stage bionutrition and biotherapeutics company. The Company is focused on the discovery, development and commercialization of products that improve muscle health and function essential for the management of sarcopenia, cachexia and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Receive News & Ratings for MYOS RENS Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS RENS Technology and related companies with MarketBeat.com's FREE daily email newsletter.